We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+31.14%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.52B
AUM Growth
+$340M
Cap. Flow
+$116M
Cap. Flow %
7.63%
Top 10 Hldgs %
75.66%
Holding
47
New
7
Increased
11
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$78.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$58M
3
BPMC
Blueprint Medicines
BPMC
+$35.3M
4
EXAS
Exact Sciences
EXAS
+$21.3M
5
NTLA icon
Intellia Therapeutics
NTLA
+$18.3M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$29.9M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$25.6M
3
MXCT icon
MaxCyte
MXCT
+$18M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$17.4M
5
DNLI icon
Denali Therapeutics
DNLI
+$16.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EQRX
1
DELISTED
EQRx, Inc. Common Stock
EQRX
$196M 12.85%
39,527,669
– –
BLFS icon
2
BioLife Solutions
BLFS
$1.56B
$172M 11.31%
7,566,292
– –
SRPT icon
3
Sarepta Therapeutics
SRPT
$1.63B
$135M 8.9%
1,225,000
+575,000
+88% +$58M
ALNY icon
4
Alnylam Pharmaceuticals
ALNY
$29.1B
$130M 8.52%
648,000
-157,000
-20% -$29.9M
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$112M 7.36%
1,700,000
+550,000
+48% +$35.3M
VERV
6
DELISTED
Verve Therapeutics
VERV
$109M 7.17%
3,178,167
+40,000
+1% +$1.28M
RLAY icon
7
Relay Therapeutics
RLAY
$4.04B
$105M 6.88%
4,683,432
+614,858
+15% +$13.5M
ILMN icon
8
Illumina
ILMN
$30.2B
$73.5M 4.83%
+395,780
New +$78.3M
MXCT icon
9
MaxCyte
MXCT
$116M
$69.8M 4.58%
10,735,786
-3,235,548
-23% -$18M
RVMD icon
10
Revolution Medicines
RVMD
$38.8B
$49.7M 3.27%
2,522,300
+152,300
+6% +$3.35M
FATE icon
11
Fate Therapeutics
FATE
$294M
$45.9M 3.02%
2,050,000
-50,000
-2% -$1.44M
SLGC
12
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$36.6M 2.4%
12,604,275
+215,193
+2% +$906K
IPSC icon
13
Century Therapeutics
IPSC
$353M
$31.7M 2.08%
3,206,380
– –
EXAS
14
DELISTED
Exact Sciences
EXAS
$31.4M 2.06%
967,000
+517,000
+115% +$21.3M
DNLI icon
15
Denali Therapeutics
DNLI
$3.67B
$30.5M 2.01%
995,000
-505,000
-34% -$16.4M
ABSI icon
16
Absci
ABSI
$1.34B
$24.2M 1.59%
7,718,593
– –
BEAM icon
17
Beam Therapeutics
BEAM
$2.66B
$17.6M 1.16%
370,000
-5,000
-1% -$285K
MRTX
18
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$17.5M 1.15%
250,000
+153,000
+158% +$11.3M
NTLA icon
19
Intellia Therapeutics
NTLA
$1.5B
$16.5M 1.08%
+295,000
New +$18.3M
ABCL icon
20
AbCellera Biologics
ABCL
$1.78B
$16.3M 1.07%
1,650,000
+900,000
+120% +$9.87M
PLRX icon
21
Pliant Therapeutics
PLRX
$64.4M
$15.7M 1.03%
+750,000
New +$14.3M
WGS icon
22
GeneDx Holdings
WGS
$1.98B
$14.4M 0.95%
498,106
– –
TWST icon
23
Twist Bioscience
TWST
$5.97B
$12.9M 0.85%
365,000
-135,000
-27% -$5.73M
TNYA icon
24
Tenaya Therapeutics
TNYA
$161M
$10.4M 0.68%
3,586,818
– –
TSVT
25
DELISTED
2seventy bio
TSVT
$8.95M 0.59%
614,754
– –
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Casdin Capital held 47 positions worth $1.52B, up 29% from $1.18B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Casdin Capital deployed $116M of net new capital in Q3 2022, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Illumina: 395,780 shares worth $73.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $29.9M trimmed.

  • Casdin Capital's largest Q3 2022 buy was Illumina: 395,780 shares worth $73.5M.
  • Casdin Capital added most to Sarepta Therapeutics in Q3 2022, an estimated $58M increase.
  • Casdin Capital's biggest Q3 2022 reduction was Alnylam Pharmaceuticals, cutting an estimated $29.9M.
  • Casdin Capital fully exited Global Blood Therapeutics, Inc. in Q3 2022, selling an estimated $25.6M.
  • Casdin Capital's ten largest holdings make up 76% of its $1.52B portfolio in Q3 2022.
  • Casdin Capital opened 7 new positions and closed 10 in Q3 2022.
  • Casdin Capital's portfolio value rose 29% quarter-over-quarter to $1.52B.

Based on Casdin Capital's 13F filing for Q3 2022, filed 14 Nov 2022.